Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection

Journal of Immunology

Volumn 161, Issue 11, 1998, Pages 6433-6438

  Fehniger, Todd A ^a,b   Herbein, Georges ^d   Yu, Haixin ^a,b   Para, Michael I ^a,c   Bernstein, Zale P ^e   O'Brien, William A ^d   Caligiuri, Michael A ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PRIORITY JOURNAL; VIRUS INHIBITION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CELL-FREE SYSTEM; CELLS, CULTURED; CHEMOKINES, CC; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 0032402307     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Biron, C. A., and R. T. Gazzinelli. 1995. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 7:485.
2. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
3. Biron, C. A. 1997. Activation and function of natural killer cell responses during viral infections, Curr. Opin. Immunol. 9:24.
4. Trinchieri, G. 1997. Cytokines acting on or secreted by macrophages during intracellular infection (IL-15, IL-12, IFN-γ). Curr. Opin. Immunol. 9:17.
5. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
6. Robertson, M. J., and J. Ritz. 1990. Biology and clinical relevance of human natural killer cells. Blood 76:2421.
7. Carson, W. E., E. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M. A. Caligiuri. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395.
8. Carson, W. E., M. E. Ross, R. A. Baiocchi, M. J. Marien, N. Boiani, K. Grabstein, and M. A. Caligiuri. 1995. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J. Clin. Invest. 96:2578.
9. Bluman, E. M., K. J. Bartynski, B. R. Avalos, and M. A. Caligiuri. 1996. Human natural killer cells produce abundant macrophage inflammatory protein-1 α in response to monocyte-derived cytokines. J. Clin. Invest. 97:2722.
10. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. de Goede, R. P. van Steenwijk, J. M. Lange, J. K. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66: 1354.
11. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563.
12. Tsubota, H., C. I. Lord, D. I. Watkins, C. Morimoto, and N. L. Letvin. 1989. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J. Exp. Med. 169:1421.
13. + T cells. Science 270:1811.
14. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661.
15. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667.
16. Wagner, L., O. O. Yang, E. A. Garcia-Zepeda, T. Ge, S. A. Kalams, S. D. Walker, M. S. Pasternack, and A. D. Luster. 1998. B-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391:908.
17. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor. Science 270:872.
18. Bleul, C. C., M. Farzan, H. Choe, C. Parolin, I. dark-Lewis, J. Sodroski, and T. A. Springer. 1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829.
19. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J. L. Virelizier, F. Arenzana-Seisdedos, O. Schwartz, J. M. Heard, I. Clark-Lewis, D. F. Legier, M. Loetscher, M. Baggiolini, and B. Moser. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833.
20. Berger, E. A., R. W. Doms, E.-M. Fenyo, B. T. M. Korber, D. R. Littman, J. P. Moore, Q. J. Satlentou, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new classification for HIV-1. Nature 391:240.
21. Bernstein, Z. P., M. M. Porter, M. Gould, B. Lipman, E. M. Bluman, C. C. Stewart, R. G. Hewitt, G. Fyfe, B. Poiesz, and M. A. Caligiuri. 1995. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86:3287.
22. Meropol, N. J., M. Porter, L. E. Blumenson, M. J. Lindemann, R. P. Perez, L. Vaickus, G. M. Loewen, P. J. Creaven, K. A. Wilkes, M. A. Giedlin, and M. A. Caligiuri. 1996. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin. Ca. Res. 2:669.
23. Bernstein, Z. P., G. Barresi, M. Gould, B. Poiesz, and M. A. Caligiuri. 1997. A phase II study of daily subcutaneous (sq) low dose interleukin-2 (IL-2) in HIV-associated malignancies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14: 40A.
24. Khatri, V. P., T. A. Fehniger, R. A. Baiocchi, Y. Feng, M. H. Shah, D. S. Schiller, M. Gould, R. T. Gazzinelli, Z. P. Bernstein, and M. A. Caligiuri. 1998. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 101:1373.
25. Matos, M. E., G. S. Schnier, M. S. Beecher, L. K. Ashman, D. E. William, and M. A. Caligiuri. 1993. Expression of a functional c-kit receptor on a subset of natural killer cells. J. Exp. Med. 178:1079.
26. O'Brien, W. A., Y. Koyanagi, A. Namazie, J. Zhao, A. Diagne, K. Idler, J. A. Zack, and I. S. Y. Chen. 1991. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 349:69.
27. Koyanagi, Y., S. Miles, R. T. Mitsuyasu, J. E. Merrill, H. V. Vinters, and I. S. Y. Chen. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819.
28. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type I. J. Virol. 66:7517.
29. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol 59:284.
30. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Dom. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149.
31. Lunardi-Iskandar, Y., J. L. Bryant, W. A. Blattner, C. L. Hung, L. Flamand, P. Gill, P. Hermans, S. Birken, and R. C. Gallo. 1998. Effects of a urinary factor from women in early pregnancy on HIV-1, SIV, and associated disease. Nat. Med. 4:428.
32. Verani, A., G. Scarlatti, M. Comar, E. Tresoldi, S. Polo, M. Giacca, P. Lusso, A. G. Siccardi, and D. Vercelli. 1997. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 185:805.
33. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367.
34. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, et al. 1996. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CKR5 chemokine receptor gene. Nature 382:722.
35. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural allele. Science 273:1856.
36. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240.
37. Paxton, W. A., S. R. Martin, D. Tse, O. B. TR, J. Skurnick, N. L. VanDevanter, N. Padian, J. F. Braun, D. P. Kotler, S. M. Wolinsky, and R. A. Koup. 1996. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2: 412.
38. Oliva, A., A. L. Kinter, M. Vaccarezza, A. Rubbert, A. Catanzaro, S. Moir, J. Monaco, L. Ehler, S. Mizell, R. Jackson, Y. Li, J. W. Romano, and A. S. Fauci. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102:223.